dactinomycin has been researched along with rasagiline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Akao, Y; Inaba-Hasegawa, K; Maruyama, W; Naoi, M | 1 |
1 review(s) available for dactinomycin and rasagiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for dactinomycin and rasagiline
| Article | Year |
|---|---|
Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Topics: Analysis of Variance; Cell Line, Tumor; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Indans; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroblastoma; Oxazoles; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Messenger; RNA, Small Interfering; Selegiline; Transfection; Up-Regulation | 2012 |